2-amino-6-methylpyrimidin-4-one

Description

2-amino-6-methylpyrimidin-4-one: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	135402055
CHEMBL ID	391757
CHEBI ID	58959
CHEBI ID	499903
SCHEMBL ID	94556
MeSH ID	M0559353

Synonyms (94)

Synonym
chebi:58959 ,
AC-2389
nsc 23662
nsc 7893
nsc 41833
nsc 13145
einecs 223-612-1
ai3-08094
BB 0243412
2-amino-6-methyl-3h-pyrimidin-4-one
k7za6h32g8 ,
unii-k7za6h32g8
nsc-7893
4-methylisocytosine
mecytosine
superacil
4(1h)-pyrimidinone, 2-amino-6-methyl-
6-methylisocytosine
nsc7893
2-amino-6-methylpyrimidin-4-ol
3977-29-5
superacyl
2-amino-6-methyl-4-pyrimidinol
2-amino-4-hydroxy-6-methylpyrimidine ,
nsc-41833
mls000737047 ,
nsc41833
nsc23662
nsc-23662
SDCCGMLS-0065525.P001
AG-670/25003504
2-amino-6-methylpyrimidin-4(3h)-one
nsc13145
nsc-13145
2-amino-6-methyl-pyrimidin-4-ol
2-amino-6-methyl-4-pyrimidol
2-amino-4-hydroxy-6-methylpyrimidine, 98%
smr000394003
A1204
CHEMBL391757
kwxipeykzkiakr-uhfffaoysa-
inchi=1/c5h7n3o/c1-3-2-4(9)8-5(6)7-3/h2h,1h3,(h3,6,7,8,9)
2-amino-6-methyl-1h-pyrimidin-4-one
CHEBI:499903
AKOS002317139
AKOS003587375
2-amino-6-methylpyrimidin-4-ol;2-amino-6-methylpyrimidin-4(1h)-one
A6638
NCGC00246942-01
HMS2743N05
2-amino-6-methyl-1,4-dihydropyrimidin-4-one
2-amino-4-methyl-6-hydroxypyrimidine
2-amino-6-methylhydropyrimidin-4-one
2-amino-6-hydroxy-4-methylpyrimidine
2-amino-6-methylpyrimidin-4(1h)-one
BP-12838
FT-0611113
AM20100050
F0827-0314
SCHEMBL94556
cid_1532
2-azanyl-6-methyl-1h-pyrimidin-4-one
bdbm73774
2-amino-6-methyl-4-pyrimidone
2-amino-6-methyl-4-pyrimidinone
2-amino-4-hydroxy-6-methyl-pyrimidine
2-amino-6-methylpyrimidin-4-one
6-methyl-isocytosine
6-methyl-iso cytosine
2 -amino-4-hydroxy-6-methyl-pyrimidine
AKOS024284331
W-106404
2-amino-4-oxo-6-methylpyrimidine
4-pyrimidinol, 2-amino-6-methyl-
2-amino-6-methyl-3,4-dihydropyrimidin-4-one
Z1530057780
F0001-1117
DTXSID90192847
mfcd00006095
GS-6812
2-imino4-hydroxy-6-methylpyrimidine
SY012702
2-imino-6-methyl-2,3-dihydro-1h-pyrimidin-4-one
2-amino-6-methyl-4-oxopyrimidine
4(3h)-pyrimidinone, 2-amino-6-methyl-
4-hydroxy-6-methyl-2-pyrimidinamine
2-amino-6-methyl-4(1h)-pyrimidinone
Q27126361
BCP26445
2-amino-4-methyl-1h-pyrimidin-6-one
EN300-100626
CS-0030573
mfcd00233528
SB57739

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

Class	Description
pyrimidone	A pyrimidine carrying one or more oxo substituents.
hydroxypyrimidine
aminopyrimidine	A member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
chromobox protein homolog 1	Homo sapiens (human)	Potency	89.1251	0.0060	26.1688	89.1251	AID540317
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ORF73	Human gammaherpesvirus 8	EC50 (µMol)	75.0000	0.0600	8.1346	32.1400	AID435023
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay ID	Title	Year	Journal	Article
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID303945	Binding affinity to BACE1 expressed in HEK293 cells by Biocore ISA	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	Discovery of a novel warhead against beta-secretase through fragment-based lead generation.
AID303944	Binding affinity to BACE1 expressed in HEK293 cells assessed as free enzyme at 1 mM after 10 mins by Biocore ISA	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	Discovery of a novel warhead against beta-secretase through fragment-based lead generation.
AID303946	Binding affinity to endothiapepsin by Biocore ISA	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	Discovery of a novel warhead against beta-secretase through fragment-based lead generation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (25.00)	29.6817
2010's	5 (62.50)	24.3611
2020's	1 (12.50)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
cytosine [no description available]	2.13	1	aminopyrimidine; pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
om99-2 OM99-2: eight-residue memapsin 2 inhibitor; structure in first source	2.03	1
2,4-diaminohypoxanthine 2,4-diaminohypoxanthine: do not confuse abbreviation DAHP with various dehydro-deoxy-arabino-heptulosonic acid phosphates which also use DAHP; RN given refers to parent cpd; structure	2.06	1	hydroxypyrimidine
pyrimidinones Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.	2.49	2

Condition	Indicated	Relationship Strength	Studies	Trials
Innate Inflammatory Response [description not available]	0	2.05	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.05	1	0

chemdatabank.com